---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-039098"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2025-04-25T23:59:59+00:00"
generated_at: "2026-05-23T05:49:10.435075+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verastem raises $75M private placement for ovarian cancer drug launch and R&D

## Summary
- Gross proceeds of ~$75M from sale of 3.43M shares at $7.00 and 7.29M pre-funded warrants at $6.9999.
- Placement led by RTW Investments; includes BVF, Nantahala, Octagon, OrbiMed, Stonepine.
- Net proceeds to fund potential launch of avutometinib/defactinib in LGSOC, R&D for VS-7375, and working capital.
- Pre-funded warrants exercisable at $0.0001/share, no expiration; closing expected April 28, 2025.

## SEC filing metadata
- accession: 0001104659-25-039098
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2025-04-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465925039098/0001104659-25-039098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465925039098/tm2513177d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-039098
- JSON: https://secwatch.observer/filing/0001104659-25-039098.json
- Plain text: https://secwatch.observer/filing/0001104659-25-039098.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.